About adlai nortye ltd - ANL
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
ANL At a Glance
Adlai Nortye Ltd.
Building 6 & 8
Hangzhou, Zhejiang 311100
| Phone | 86-571-289-8385 | Revenue | 5.01M | |
| Industry | Miscellaneous Commercial Services | Net Income | -35,621,962.17 | |
| Sector | Commercial Services | Employees | 109 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ANL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.057 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.38 |
| Enterprise Value to Sales | 9.573 |
| Total Debt to Enterprise Value | 0.55 |
ANL Efficiency
| Revenue/Employee | 45,992.878 |
| Income Per Employee | -326,806.992 |
| Receivables Turnover | 3.607 |
| Total Asset Turnover | 0.095 |
ANL Liquidity
| Current Ratio | 0.646 |
| Quick Ratio | 0.646 |
| Cash Ratio | 0.571 |
ANL Profitability
| Gross Margin | N/A |
| Operating Margin | -721.88 |
| Pretax Margin | -710.50 |
| Net Margin | -710.56 |
| Return on Assets | -67.40 |
| Return on Equity | -415.104 |
| Return on Total Capital | -197.307 |
| Return on Invested Capital | -380.68 |
ANL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 146.095 |
| Total Debt to Total Assets | 76.601 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 6.242 |